Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 known ✓ | Q04771 | 15/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.98 |
| ▸ | ACVR1B | P36896 | 14/20 | 0.98 |
| ▸ | BMPR1A | P36894 | 14/20 | 0.98 |
| ▸ | ACVRL1 | P37023 | 14/20 | 0.98 |
| ▸ | BMPR1B | O00238 | 12/20 | 0.98 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.98 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.98 |
| ▸ | BMPR2 | Q13873 | 4/20 | 0.98 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.98 |
| ▸ | BMP4 | P12644 | 4/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.98 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22462135 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL29634729 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL29373122 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL456393 | 0.99 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL29353046 | 0.99 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hypochlorous Acid SCHEMBL26968209 | 0.96 | ACVR1B (0.94) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL30388107 | 0.93 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL24908393 | 0.93 | ACVR1B (0.89) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL16025991 | 0.92 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL29391702 | 0.92 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065671-B2 | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-20 | — | — | US | claimed |
| EP-4345160-A2 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-03 | — | — | EP | claimed |
| EP-3347456-B1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | US HEALTH (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230151336-A1 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-18 | — | — | US | claimed |
| WO-2021216846-A9 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-16 | — | — | WO | claimed |
| WO-2021216846-A2 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210139847-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-13 | — | — | US | claimed |
| US-20190169569-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-06-06 | — | — | US | claimed |
| EP-3347456-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044483-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-16 | — | — | WO | claimed |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | UNIV MINNESOTA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4680255-A1 | METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340836-A1 | METHODS FOR PRODUCTION OF IPSCS | NEW YORK STEM CELL FOUND INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-9045484-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2265603-B1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | GEN HOSPITAL CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | ACVR1 9/4885KDR 260/4885ACVR1B 11/4885 |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | FGFR2, FGF2, FGF1 | ACVR1 89/4885KDR 299/4885ACVR1B 115/4885 |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | LGALS1, LGALS9, ALDH1A2 | ACVR1 160/4885KDR 238/4885ACVR1B 673/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | ACVR1 9/4885KDR 260/4885ACVR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.